MIRM — Mirum Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $93.33
- 30-Day Move
- +45.6%
- Market Cap
- $5.7B
- Shares Outstanding
- 60,340,000
- P/B Ratio
- 12.97
- ROE
- -7.4%
Mirum Pharmaceuticals Inc
A read-only Alphactor snapshot forMirum Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$93.33
30-Day Move
+45.6%
Market Cap
$5.7B
Shares Outstanding
60,340,000
P/B Ratio
12.97
ROE
-7.4%
$93.33
+45.6%last 90 delayed daily bars
90D High
$109.28
90D Low
$63.23
Avg Volume
829,240
Gross margin is running at 80.8%, which gives a quick read on operating quality before you open the full model.
Net margin is -4.5%, useful for comparing MIRM against peers in Biotechnology.
MIRM is up 45.6% over the last 30 trading days shown on this page.
Latest operating income is $-22M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$60.47
Rule of 40
65.3%
Latest Close
$93.33
30-Day Move
+45.6%
Market Cap
$5.7B
Shares Outstanding
60,340,000
P/B Ratio
12.97
ROE
-7.4%
ROA
-2.8%
Gross Margin
80.8%
Operating Margin
-4.3%
Net Margin
-4.5%
Debt / Equity
0.98
Current Ratio
2.67
Latest Revenue
$521M
Revenue
$521M
Gross Profit
$421M
Operating Income
$-22M
Net Income
$-23M
Gross Margin
8077.0%
Net Margin
-448.0%
Current Ratio
2.67
Debt / Equity
0.98
Fair Value
$60.47
Upside / Downside
-35.2%
Signal
Overvalued
Implied Growth
28.6%
DCF
$78.12
EV/Rev
$42.82
Growth Assumption
50.0%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$55M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
6.37
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
-2.39x
Rule of 40
65.3%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $77M | $-131M | $-136M | $-120M |
| 2023-12-31 | $186M | $-109M | $-163M | $-91M |
| 2024-12-31 | $337M | $-88M | $-88M | $-11M |
| 2025-12-31 | $521M | $-22M | $-23M | $55M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,349,769 | 0.02% | 2025-12-31 |
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 1,309,135 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 993,288 | 0.02% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 966,349 | 0.02% | 2026-03-31 |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 798,067 | 0.01% | 2025-12-31 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 770,383 | 0.01% | 2025-12-31 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 682,692 | 0.01% | 2025-12-31 |
| Legg Mason Partners Investment Trust-ClearBridge Small Cap Growth Fund | 544,097 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Vanguard Group
Filed 2026-01-29
$205M
+2.0%
BlackRock
Filed 2024-08-13
$111M
--
Geode Capital Management
Filed 2026-02-09
$84M
+5.2%
Citadel Advisors
Filed 2025-11-14
$76M
--
D.E. Shaw
Filed 2026-02-17
$75M
+2.7%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.